84 / 144
84
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
25. Chin HS, Park TS, MoonYS, Oh JH. Difference in clearance of intravitreal triamcinolone
acetonide betweewn vitrectomized and nonvitrectomized eyes. Retina 2005; 25:556-
560.
26. Chen YY, Chen PY, Chen FT, Chen YJ, Wang JK. Comparison of ef%cacy of intravitreal
ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular
edema. Int Ophthalmol. 2017 Feb 7. doi: 10.1007 / s10792-017-0462-1. [Epub ahead
of print].
27. Bressler SB, Melia M, Glassman AR et al. Ranibizumab plus prompt or deferred laser
for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial
growth factor therapy. Retina. 2015; 35: 2516-2528.
28. Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: swi-
tching anti-VEGF treatments, adopting corticosteroid based treatments, and combina-
tion therapy, Expert Opinion on Biological Therapy. 2016; 16:3, 365-374.
29. Bressler SB, Ayala AR et al. Persistent Macular Thickening After Ranibizumab Treat-
ment for Diabetic Macular Edema With Vision Impairment JAMA Ophthalmol. 2016;
134(3):278-285.
30. poster 41 “Association between early BCVA response to anti-VEGF therapy at 13 weeks
and average improvement in BCVA over 3 years: a post-hoc “area under curve” analysis
of protocol I Anat Lowenstein et al.”, apresentado emVarsóvia em 2016.
31. Gonzalez VH, Campbell J, Holekamp NM et al. Early and Long-Term Responses to
Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis
of Protocol I Data. Am J Ophthalmol. 2016;172:72-79.
32. Gower et al. Adverse Event Rates Following Intravitreal Injection of Avastin or Lucen-
tis for Treating Age-Related Macular Degeneration, poster apresentado em congresso
ARVO 2011.
33. Carneiro et al. Arterial Thromboembolic Events in Patients with Exsudative Age-Rela-
ted Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab.
Ophthalmologica. 2011;225:211-221.
34. Sharma S et al. Rate of serious adverse effects in a series of bevacizumab and ranibizu-
mab injections. Can J Ophthalmol. 2012;47:275-279.
35. Souied EH et al. Severe Ocular In`ammation Following Ranibizumab or A`ibercept
Injections for Age- Related Macular Degeneration: A Retrospective Claims Database
Analysis. Ophthalmic Epidemiology. 2016;23(2): 71-79.